Login / Signup

Treatment of refractory myasthenia gravis by double-filtration plasmapheresis and rituximab: A case series of nine patients and literature review.

Hamza N BennaniEmmeline LagrangeJohan NoblePaolo MalvezziLionel MotteEloi ChevallierLionel RostaingThomas Jouve
Published in: Journal of clinical apheresis (2020)
The combination of rituximab and DFPP was effective to treat refractory MG.
Keyphrases
  • myasthenia gravis
  • end stage renal disease
  • diffuse large b cell lymphoma
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • hodgkin lymphoma
  • case report